7-5/2013/EU/WC-0127 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated

1 MAT 20211

To

M/s. Solara Active Pharma Sciences Limited A1/B, SIPCOT Industrial Complex Kudikadu, Cuddalore - 607 005

SUB:- Written Confirmation of M/s. Solara Active Pharma Sciences Limited, A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore - 607 005 as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, South Zone office, and the recommendation received from DDC (I), South Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
 - The manufacturer is subject to regular, strict and transparent controls and to the
 effective enforcement of Good Manufacturing Practice, including repeated and
 unannounced inspections, so as to ensure a protection of public health equivalent
 to that in the EU.
 - 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
 - 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
 - 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

- This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.


Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
01	21	05.08.2019	04.08.2022
02	06	05.08.2019	04.08.2022
03	03	09.09.2019	04.08.2022
04	01	03.10.2019	04.08.2022
05	01	28.01.2020	04.08.2022
06	01	28.04.2020	04.08.2022
07	02	3 1 MAY 2021	04.08.2022

Yours faithfully,

(Dr. V. G. Somani) Drugs Controller General (India)

0/0



CERTIFICATE NO. :

WC-0127

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Solara Active Pharma Sciences Limited

A1/B, SIPCOT Industrial Complex Kudikadu, Cuddalore - 607 005

List of APIs:

Sr. Io.	Active substance (s)	Activity(ies)	
1.	Ibuprofen Lysine		
2.	Ibuprofen Arginine	Manufacturing & Packing	
		Manufacturing & Packing	

ITEM(S) TWO (02) ONLY

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: Three years from date of issue

Signature

0/0

the authority and date

3 1 MAY 2021